The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide) – but adds in activity against glucagon. That three-pronged attack helped ...

Lilly’s candidate to activate the GLP-1, GIP, and glucagon receptors is an engineered peptide named retatrutide. Acknowledging the caveats that come with cross-trial comparisons, Phase 2 results ...

Retatrutide's interaction with the GCGR suggests a potential role in lipid mobilization and oxidation. By activating glucagon receptors, Retatrutide is theorized to promote the breakdown of stored ...

Eli Lilly has already got a GIP, GLP-1 and glucagon agonist into late-stage development in the form of retatrutide, which was tied to a 16% weight loss at 24 weeks in a phase 2 study in 2023.

The Retatrutide Peptide is a key compound in our product portfolio. It is designed for experimental use only. This peptide is not for human consumption. Instead, it serves research purposes in ...

Retatrutide's potential to activate the GCGR in addition to the GLP-1 receptor suggests it may have a broader impact on metabolic regulation. Activating glucagon receptors might support lipid ...